---
title: "Beyond Air, Inc. FY 2026: Revenue $7.7M, EPS $(4.01) — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291004020.md"
description: "Beyond Air, Inc. reported FY2026 results with revenue of $7.7M, up 107% YoY, driven by hospital contracts and international sales. The company recorded a net loss of $(33.2) M and diluted EPS of $(4.01), both improvements from FY2025. Key highlights include U.S. commercial marketing of LungFit® PH following FDA PMA and EU CE mark achievement. R&D spending decreased as Gen II development slowed, while operational upgrades supported commercialization efforts."
datetime: "2026-06-26T20:15:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291004020.md)
  - [en](https://longbridge.com/en/news/291004020.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291004020.md)
generator: "portal-rs"
---

# Beyond Air, Inc. FY 2026: Revenue $7.7M, EPS $(4.01) — 10-K Summary

Beyond Air, Inc. reported fiscal 2026 results showing revenue of $7.7M, up from $3.7M a year earlier, while the company recorded a net loss attributable to Beyond Air, Inc. of $(33.2) M and diluted loss per share of $(4.01) for the year ended March 31, 2026.

**Financial Highlights**

-   Revenue: $7.7M for year ended March 31, 2026, compared with $3.7M in FY 2025; YoY change 107%.
-   Net income: Net loss attributable to Beyond Air, Inc. $(33.2) M for year ended March 31, 2026, improved from $(46.6) M in FY 2025.
-   Diluted EPS: Loss per share $(4.01) for year ended March 31, 2026, improved from $(13.77) in FY 2025.

**Business Highlights**

-   Revenue growth was driven by expanding hospital contracts and increased international sales.
-   Began U.S. commercial marketing of LungFit® PH following FDA PMA in June 2022 and achieved CE mark in the EU in November 2024.
-   Sales channels include hospitals and ventilator channels; company is also deploying devices for mask delivery >100ppm for severe lung infections.
-   R&D spending was reduced as Gen II device development slowed; subsidiaries Beyond Cancer and NeuroNos continue preclinical work and Phase 1b planning.
-   Operationally, the company upgraded its device fleet, recorded one‑time inventory provisions, and expanded device purchases to support commercialization.

Original SEC Filing: Beyond Air, Inc. \[ XAIR \] - 10-K - Jun. 26, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [XAIR.US](https://longbridge.com/en/quote/XAIR.US.md)

## Related News & Research

- [XAIR: Flat revenue, improved margins, and strong outlook hinge on FDA approval and new product launch](https://longbridge.com/en/news/295788812.md)
- [Starfighters Space, Inc. GAAP EPS of -$0.24](https://longbridge.com/en/news/296400745.md)
- [08:36 ETBCA IT, Inc. Named No. 1700 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America's Fastest-Growing Private Companies](https://longbridge.com/en/news/296229672.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**